Back to search

Article

Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer

2020-02-24

Abstract excerpt

<title>Abstract</title> <p>Background: Estrogen receptor (ER) positive breast cancer is often effectively treated with drugs that inhibit ER signaling, i.e., tamoxifen (TAM) and aromatase inhibitors (AIs). However, 30% of ER+ breast cancer patients develop resistance to therapy leading to tumour recurrence. Changes in the methylation profile have been implicated as one of the mechanisms through which therapy resi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
aab9d858-334c-5a4d-847b-256cfaa50366
DOI
10.21203/rs.2.17518/v2
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancerDOI 10.21203/rs.2.17518/v2
Candidate methylation sites associated with endocrine therapy resistance in the TCGA ER+/HER2- breast cancer cohortSemantic proximity
Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differencesSemantic proximity
A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders.Semantic proximity
Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumoursSemantic proximity
Novel Gene Signatures Predictive of Patient Recurrence-free Survival in HR+HER2- Breast CancerSemantic proximity
Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast CancerSemantic proximity
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancerSemantic proximity
Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancerSemantic proximity
Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancersSemantic proximity
Investigation of the Genomic and Transcriptomic Variations Underlying Tamoxifen Resistance in Breast CancerSemantic proximity
ENDORSE: a prognostic model for endocrine therapy response in advanced estrogen-receptor positive breast cancersSemantic proximity
Characterizing novel molecular mechanisms involved in breast cancer tumourigenesis/progression and tamoxifen resistanceSemantic proximity
Select a neighboring publication to make it the new centre.